糖尿病性腎症の市場規模、シェア、成長分析：薬剤クラス別、タイプ別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025年～2032年

糖尿病性腎症の世界市場規模は2023年に23億米ドルと評価され、2024年の24億4,000万米ドルから2032年には38億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.0％で成長する見通しです。

世界の糖尿病性腎症市場は、主に糖尿病の有病率の上昇と効果的な治療ソリューションに対するニーズの高まりによって、大幅な成長を遂げています。糖尿病は世界の流行レベルに達しており、罹患人口のかなりの部分が糖尿病性腎症を発症するリスクにさらされているため、高度な治療オプションに対する需要が高まっています。我々の分析によると、医学研究の継続的な進歩により、バイオマーカーや遺伝子検査などの新しい診断ツールがイントロダクションされ、早期発見やリスク評価が強化されています。さらに、レニン-アンジオテンシン-アルドステロン系（RAAS）阻害薬やナトリウム-グルコース共輸送体2（SGLT2）阻害薬などの標的治療薬の登場により、疾患の進行を遅らせたり合併症を軽減したりすることで、疾患管理が大幅に改善されています。これらのブレークスルーは市場の技術革新を促進し、患者の転帰を改善し、市場の大幅な拡大を促しています。ヘルスケアプロバイダーが早期介入と個別化治療を重視する中、糖尿病性腎症市場は継続的な成長の態勢を整えています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

糖尿病性腎症市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 利尿剤
• 抗酸化炎症調節剤
• アンジオテンシン受容体遮断薬
• アンジオテンシン変換酵素阻害剤（ACE阻害剤）
• レニン阻害剤
• カルシウムチャネル遮断薬
• その他

糖尿病性腎症市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 1型糖尿病
• 2型糖尿病

糖尿病性腎症市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• その他

糖尿病性腎症市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• ホームケア
• 専門センター
• その他

糖尿病性腎症市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局

糖尿病性腎症市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Eli Lilly and Company（US）
• AstraZeneca（UK）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Sanofi（France）
• Merck & Co., Inc.（US）
• Daiichi Sankyo Company, Limited（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Boehringer Ingelheim（Germany）
• GlaxoSmithKline plc（UK）
• AbbVie Inc.（US）
• Vertex Pharmaceuticals（US）
• Amgen（US）
• Gilead Sciences, Inc.（US）
• Biogen（US）
• Regeneron Pharmaceuticals, Inc.（US）

結論と推奨事項

Global Diabetic Nephropathy Market size was valued at USD 2.3 billion in 2023 and is poised to grow from USD 2.44 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global diabetic nephropathy market is witnessing substantial growth, primarily fueled by the rising prevalence of diabetes and the increasing need for effective treatment solutions. With diabetes reaching epidemic levels worldwide, a significant portion of the affected population is at risk of developing diabetic nephropathy, creating a growing demand for advanced therapeutic options. Our analysis reveals that continuous advancements in medical research have led to the introduction of novel diagnostic tools, such as biomarkers and genetic testing, enhancing early detection and risk assessment. Furthermore, the emergence of targeted therapies, including renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors, has significantly improved disease management by slowing disease progression and mitigating complications. These breakthroughs are driving innovation in the market, ensuring better patient outcomes and fostering substantial market expansion. As healthcare providers emphasize early intervention and personalized treatments, the diabetic nephropathy market is poised for continued growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Nephropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Nephropathy Market Segments Analysis

Global Diabetic Nephropathy Market is segmented by Drug Class, Type, Route of Administration, End-Users, Distribution Channel and Region. Based on Drug Class, the market is segmented into Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers and Others. Based on Type, the market is segmented into Type-1 Diabetes and Type-2 Diabetes. Based on Route of Administration, the market is segmented into Oral, Parental and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Nephropathy Market

Our analysis reveals that the rising healthcare expenditure, especially in emerging economies, is a key driver propelling the growth of the global diabetic nephropathy market. Increasing investments in healthcare infrastructure are improving access to advanced diagnostics, effective treatment modalities, and essential medications for diabetic nephropathy patients. Governments and private entities are allocating substantial resources to enhance disease management programs, early detection initiatives, and specialized care facilities. This growing financial commitment is fostering a more robust healthcare ecosystem, enabling patients to receive timely and comprehensive treatment. As healthcare budgets continue to expand, particularly in regions with a high diabetes burden, the diabetic nephropathy market is expected to witness sustained growth, driven by improved affordability and availability of critical medical interventions.

Restraints in the Global Diabetic Nephropathy Market

Our analysis reveals that the high cost of diabetic nephropathy treatment remains a significant restraint in the global market. Advanced therapeutic options, including SGLT2 inhibitors, RAAS inhibitors, and dialysis, impose a substantial financial burden on patients, particularly in low- and middle-income countries where healthcare reimbursement is limited. Additionally, kidney transplants, often the last resort for end-stage renal disease (ESRD) caused by diabetic nephropathy, involve extensive costs for surgery, post-operative care, and lifelong immunosuppressive therapy. This financial barrier leads to delayed treatment initiation, worsening disease progression, and higher mortality rates. Moreover, the lack of affordable generic alternatives further exacerbates accessibility challenges, restricting market expansion, especially in regions with inadequate healthcare infrastructure and limited insurance coverage.

Market Trends of the Global Diabetic Nephropathy Market

One of the key trends shaping the global diabetic nephropathy market is the rising cost of healthcare, which is driving demand for more cost-effective and efficient treatment solutions. Additionally, the growing emphasis on personalized medicine is revolutionizing disease management by enabling tailored treatment approaches based on individual patient profiles. As the market expands, significant advancements in innovative therapies, including precision medicine, targeted biologics, and novel drug formulations, are expected to emerge. These innovations aim to enhance treatment efficacy, improve patient outcomes, and reduce disease progression. Our analysis reveals that continued investment in research and development will play a crucial role in transforming diabetic nephropathy care, ultimately leading to improved quality of life for affected individuals worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Diabetic Nephropathy Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Diuretics
• Antioxidant Inflammation Modulator
• Angiotensin Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
• Renin Inhibitors
• Calcium Channel Blockers
• Others

Global Diabetic Nephropathy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Type-1 Diabetes
• Type-2 Diabetes

Global Diabetic Nephropathy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parental
• Others

Global Diabetic Nephropathy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Centers
• Others

Global Diabetic Nephropathy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Diabetic Nephropathy Market Size & CAGR (2025-2032)

• North America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations